Navigation Links
Unlocking the genetic and molecular mystery of soft-tissue sarcoma
Date:11/30/2011

BostonNOVEMBER 30, 2011Scientists at Joslin Diabetes Center in Boston have uncovered important molecular and genetic keys to the development of soft-tissue sarcomas in skeletal muscle, giving researchers and clinicians additional targets to stop the growth of these often deadly tumors.

Published in the Proceedings of the National Academy of Sciences, the study identified two major molecular signaling pathways (the Ras and mTOR pathways) that are common in tumor growth and development. These molecular pathways regulate cell growth and division, two cellular properties whose over-activation are hallmarks of cancer biology.

"In humans, some sarcomas respond to chemotherapy," says lead author Amy J. Wagers, PhD, an associate professor of stem cell and regenerative biology at Harvard Medical School and Joslin Diabetes Center, "but many don't. With these findings, we have vetted a list of new candidate targets whose inhibition may lead to regression of these tumors. "

Many soft-tissue sarcomas, which develop in certain tissues such as bone and muscle, carry specific genetic mutations or unique gene signatures, which can allow scientists to develop more precise, targeted therapies. Wagers and her colleagues engineered a tumor system in mice by introducing into mouse skeletal muscle a cancer-carrying gene, or oncogene, known to cause tumors in humans. They used this engineered system to identify a small set of genes that are active in sarcoma tumors.

There are many different types of soft-tissue sarcomas, which develop in tissues that connect, support or surround other structures and organs, including muscle, tendons, nerves, fat and blood vessels. If diagnosed early, treatment, primarily through surgical removal of the tumor, radiation therapy or chemotherapy, can be effective. If the tumor has spread, however, the tumor can be controlled only for a period of time, but treatment does not often cure the disease.

B
'/>"/>

Contact: Jeffrey Bright
jeffrey.bright@joslin.harvard.edu
617-309-1957
Joslin Diabetes Center
Source:Eurekalert  

0

GOOD

Page: 1 2

Related medicine news :

1. Unlocking jams in fluid materials
2. UNC researchers inch closer to unlocking potential of synthetic blood
3. Unlocking the secret of beauty: Scientists discover the complexities of attractive female bodies
4. Unlocking the Immune System's Response to Infection and Injury
5. CU-Boulder led study of smoking twins points to growing influence of genetic factors
6. Increasing dosage of clopidogrel for patients with genetic variation improves response to medication
7. Combination epigenetic therapy clinical trial results
8. Epigenetic therapy shows promise in hard-to-treat lung cancer
9. Breakthrough in understanding the genetics of high blood pressure
10. Possible Genetic Link to Autism Identified
11. Ohio State researchers design a viral vector to treat a genetic form of blindness
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Unlocking the genetic and molecular mystery of soft-tissue sarcoma
(Date:6/18/2013)... Palo Alto has taken yet another step in ... its recent major long-term solar power commitment. , Last ... power purchase agreements , which together will result in the ... electric power per year, which is the equivalent of roughly ... power to supply all 65,000+ Palo Alto residents---and then some! ...
(Date:6/18/2013)... New York, NY (PRWEB) June 18, 2013 ... M2a Magnum hip continue to move forward in a ... Indiana, Bernstein Liebhard LLP reports. According to court ... on June 17th, at which time the Court also ... scientific and technical issues pertinent to the Biomet hip ...
(Date:6/18/2013)... June 18, 2013 Sun Buick GMC, Moosic, ... Health Services 20th Annual Golf Tournament on Thursday, June 20, ... hole-in-one prize is a 2013 Buick Verano and will go ... a hole-in-one on Irem’s 7th hole. , The MFHS golf ... is a four person captain and crew team for 18 ...
(Date:6/18/2013)... 18, 2013 Seven-year-old Riley Salz of ... autism. He receives 40 hours a week of applied ... from the Center for Autism and Related Disorders (CARD). ... 2008, and has experienced remarkable progress, including learning to ... environment. Riley’s personal journey through autism is now featured ...
(Date:6/18/2013)... 18, 2013 Internationally acclaimed plastic ... website, thebestbreast.com, showcasing his unique approach to breast ... about his surgical method and highlights the results ... his website, Dr. Tebbetts compares his breast augmentation ... Dr. Tebbetts’ method does not necessitate the use ...
Breaking Medicine News(10 mins):Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 2Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 3Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website 2
... M. Miano, Ph.D associate professor within the Cardiovascular Research ... that // small regulatory DNA sequences control ... scanned the vast human DNA code to reveal 60 ... of the study were published in the journal Genome ...
... one of the National Institutes of Health has awarded ... Infectious Disease Agent Study (MIDAS) grants to // ... research team. , The goal of this ... techniques. These techniques would be used later to quickly ...
... treatment benefits with your doctor does not seems to benefit ... Colleagues, University of California, San Francisco found in a study ... and shared the decision with their doctor. ,The ... patient did not benefit the patient in deciding the symptoms ...
... has revealed that investing more money in the country’s healthcare ... necessarily// result in better services. The manner in which the ... the author of the report. The name of the report ... healthcare system in the country is available at British Columbia, ...
... for rotavirus has been approved by the US. The rotavirus ... of about 500,000 children across the world annually. // In ... medicine's maker tested the vaccine on more than 70,000 children ... ,Rotavirus is a highly contagious virus that causes severe dehydrating ...
... will be recruiting Indian nurses to overcome the shortage of ... Nursing at Medi-Clinic, told the Afrikaans daily Beeld here that ... for India to start a selection process for 60 clinical ... project in the Western Cape Province, where the shortage of ...
Cached Medicine News:Health News:Human Complexity Can Be Attributed To Regulatory Sequence 2Health News:Detecting Epidemics using statistics 2
(Date:6/18/2013)... MT. PROSPECT, Ill. , June 18, 2013 ... availability of its new X3130 Appliance Inlet Module. ... thermal circuit breaker , combines a C14 appliance ... in one compact package.  This three-in-one device allows ... in their designs - cutting installation time by ...
(Date:6/18/2013)... N.J. , June 18, 2013  Actavis, Inc. (NYSE: ... Actavis") has filed with the U.S. Securities and Exchange Commission ... Actavis, proposed acquisition of Warner Chilcott plc (NASDAQ: ... of Actavis and Warner Chilcott (the "Form S-4"). ... and Warner Chilcott have entered into a definitive ...
(Date:6/18/2013)... , June 18, 2013  It has ... of Alliance Seating and Mobility, a subsidiary company ... access timely repair. This appears to be due ... reduction of field service employees.  ... great many of these clients are complex mobility ...
Breaking Medicine Technology:Three-in-One X3130 Appliance Inlet Module 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7
... 21, 2010 Takeda Pharmaceutical Company Limited ("Takeda") ... Takeda Pharmaceuticals North America, Inc. ("TPNA"), have completed ... against the companies in response to their Abbreviated ... HCl), ACTO plus met® (pioglitazone HCl and ...
... Dec. 21, 2010 Today, Pepex Biomedical, Inc. announced ... $244,479.25 under the Qualifying Therapeutic Discovery Project created by ... Affordable Care Act of 2010, the major health care ... March 23, 2010.  Pepex submitted their ground-breaking, patented, electrochemical ...
Cached Medicine Technology:Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 2Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 3Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 4Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 5Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 6Pepex™ Awarded Qualifying Therapeutic Discovery Project Grant 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: